Daan Biotherapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $21.3M

  • Investors
  • 16

Daan Biotherapeutics General Information

Description

Operator of an integrated immune-oncology drug research firm intended to find various treatment strategies and offer new lung cancer drugs. The company uses anticancer immune cell therapy using Natural Killer cells and T cell receptors, and clinical trials based on an independent research infrastructure, enabling healthcare providers with cell therapies, antibodies, and small molecule inhibitors to treat cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3th Floor, 366, Hangang-daero
  • Yongsan-gu
  • Seoul, 04323
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 3th Floor, 366, Hangang-daero
  • Yongsan-gu
  • Seoul, 04323
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Daan Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 25-Jan-2024 $21.3M Completed Generating Revenue
1. Seed Round 28-Mar-2022 Completed Pre-Clinical Trials
To view Daan Biotherapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Daan Biotherapeutics Patents

Daan Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026192355-A1 Novel serum albumin-binding single domain antibody Pending 10-Mar-2025
WO-2026019161-A1 Novel anti-ceacam5 antibody and therapeutic agent use thereof Pending 19-Jul-2024
JP-2026536668-A Anti-ceacam5 antibody and its uses Pending 09-Nov-2023
AU-2024375661-A1 Anti-ceacam5 antibody and use thereof Pending 09-Nov-2023
EP-4806921-A1 Anti-ceacam5 antibody and use thereof Pending 09-Nov-2023 A61K39/00
To view Daan Biotherapeutics’s complete patent history, request access »

Daan Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Daan Biotherapeutics Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Atinum Investment Venture Capital Minority
DAYLI Partners Venture Capital Minority
FuturePlay Venture Capital Minority
Heungkuk Securities Corporation Minority
KB Investment Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Daan Biotherapeutics FAQs

  • When was Daan Biotherapeutics founded?

    Daan Biotherapeutics was founded in 2020.

  • Where is Daan Biotherapeutics headquartered?

    Daan Biotherapeutics is headquartered in Seoul, South Korea.

  • What is the size of Daan Biotherapeutics?

    Daan Biotherapeutics has 6 total employees.

  • What industry is Daan Biotherapeutics in?

    Daan Biotherapeutics’s primary industry is Drug Discovery.

  • Is Daan Biotherapeutics a private or public company?

    Daan Biotherapeutics is a Private company.

  • What is Daan Biotherapeutics’s current revenue?

    The current revenue for Daan Biotherapeutics is .

  • How much funding has Daan Biotherapeutics raised over time?

    Daan Biotherapeutics has raised $25.4M.

  • Who are Daan Biotherapeutics’s investors?

    Atinum Investment, DAYLI Partners, FuturePlay, Heungkuk Securities, and KB Investment are 5 of 16 investors who have invested in Daan Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process